Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Alopecia areata
- Focus Registrational; Therapeutic Use
- Acronyms BRAVE-AA1
- Sponsors Eli Lilly and Company
- 01 Mar 2024 Results (from studies BRAVE-AA1 and BRAVE-AA2) assessing efficacy and safety of baricitinib for severe AA through 104 weeks of continuous therapy published in the Journal of the European Academy of Dermatology and Venereology
- 30 Jan 2024 According to a Eli Lilly Canada Inc. media release, OLUMIANT (baricitinib) received regulatory approval for alopecia areata indication via Notice of Compliance (NOC) from Health Canada,The approval is based on BRAVE-AA1 and BRAVE-AA2 trials
- 22 Nov 2023 Results of Post-, pooled Analysis from BRAVE AA1 and BRAVE AA2, published in the Dermatology and Therapy